Defendant
1 case as defendant.
Hetero USA Inc. is the U.S. sales and marketing arm of Hetero, a privately owned, research-based global pharmaceutical company founded in 1993 and headquartered in Hyderabad, India. Hetero USA Inc. was established in 2010 and is based in Piscataway, New Jersey. The U.S. subsidiary has an estimated annual revenue of $1-$10 million and employs approximately 21-50 people.
The company's operations in the U.S. focus on Active Pharmaceutical Ingredients (APIs) and Custom Pharmaceutical Services (CPS). Globally, Hetero is a significant producer of APIs and generic formulations, with a presence in over 140 countries. Their diverse product portfolio includes antiretrovirals (Hetero is the world's largest producer of anti-retroviral drugs), antineoplastics, antiulcerants, cardiovascular drugs, antidepressants, and antidiabetics, among others. Hetero also develops and markets biosimilars and over-the-counter products.
Hetero USA Inc. appears in patent litigation as a defendant, consistent with an operating company that produces pharmaceutical products. The company has been involved in one tracked case, appearing solely as a defendant.
The sole tracked case involving Hetero USA Inc. is Otsuka Pharmaceutical Co., Ltd. v. Hetero USA Inc. et al., filed in the District of Delaware on April 4, 2014.
Otsuka Pharmaceutical Co., Ltd. filed suit against Hetero USA Inc., Hetero Labs Ltd. Unit V, and Hetero Labs Limited in the District of Delaware regarding US Patent 8501730. The outcome of the case is not detailed.